SET A

While the Open Access premise of “no barriers for readers to access content” and the reasons for it have been well-publicized, many journal publishers are still wrestling with questions about its financial viability. This panel of experts will provide background on the initiative, and will explore some of the economic models being used to carry it forward.

A2. Standards of Reporting Biomedical Research: What’s New?
Sabine Kleinert, Executive Editor, The Lancet
David Moher, PhD, Assistant Professor of Pediatrics, Medicine, and Epidemiology and Community Medicine, Chalmers Research Group Childrens’ Hospital of Eastern Ontario Research Institute
Hal Sox, MD, Editor, Annals of Internal Medicine
Faith McLellan, PhD, North American Senior Editor, The Lancet (Moderator)

Many biomedical journals require submitted papers to conform to various standards (statements, checklists, flow diagrams, etc.) that have been developed to improve the quality of reporting research results. The CONSORT (Consolidated Standards of Reporting Trials) statement and STARD (Standards for the Report of Studies on Diagnostic Accuracy) are two such tools. Speakers in this session will discuss the latest developments in reporting standards, along with their advantages and drawbacks.

A3. Legal Requirements and Ramifications of Conducting Clinical Trials
Mehmood Khan, MD, FACE, Vice President, Medical and Scientific Affairs,Takeda Pharmaceuticals North America
Richard C. Ascroft, RPh, JD, Manager of Federal Affairs, Public Policy Planning and Development, Eli Lilly and Company
Robert L. Frye, MD, Professor of Medicine, Mayo Clinic College of Medicine; Brad Glazer, Senior Publication Manager, Takeda Pharmaceuticals North America (Moderator)

The pharmaceutical industry operates in a heavily regulated environment. Given the stringent rigor with which clinical trials are planned and conducted, this session is designed to share information on the drives surrounding this regulated environment. Speakers from the pharmaceutical industry and academia will cover the ethical, legal, and regulatory requirements and responsibilities of conducting clinical research.

A4. The Effect of Primary Publishers’ Journal Changes on Secondary Publishers
Linda Beebe, Senior Director, PsycINFO, American Psychological Association
Ted Freeman, Director of Electronic Publishing, Allen Press, Inc.
Isabel Czech, Director, Publisher Relations, Thompson Institute for Scientific Information
Annielaurie Seifert, Account Manager, Allen Press, Inc. (Moderator) When primary publishers began publishing electronically, a uniform standard had not been established to enable secondary publishers to process that content. Primary content ended up being “uncitable” and researchers could neither find what they needed nor cite it in their work. In this electronic era, the standards remain insufficient for secondary publishers to process the data. The problems these panelists encountered and potential “fixes” for the future will be discussed.

A5. Archiving: What Are the Projects and the Needs?
Vicky Reich, HighWire Press
Margaret Perkins, Chief Manuscript Editor, University of Chicago Press (Moderator)
Other(s) to be added

Materials published in electronic form may become virtually inaccessible within months after publication. As the quantity of published electronic-only material increases, the need for ways not only to store and allow access to the material but also to make it easy to find becomes urgent. Learn more about the projects designed to address this growing problem.